M&A Deal Summary

Envision Pharma Acquires doDOC

On March 22, 2021, Envision Pharma acquired internet software and services company doDOC

Acquisition Highlights
  • This is Envision Pharma’s 1st transaction in the Internet Software and Services sector.
  • This is Envision Pharma’s 3rd transaction in the United States.
  • This is Envision Pharma’s 1st transaction in Massachusetts.

M&A Deal Summary

Date 2021-03-22
Target doDOC
Sector Internet Software and Services
Buyer(s) Envision Pharma
Deal Type Add-on Acquisition

Target

doDOC

Boston, Massachusetts, United States
doDOC is a Software as a Service (SaaS)-based platform that enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today. doDOC was founded in 2015 and is based in Boston, Massachusetts.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Envision Pharma

Horsham, United Kingdom

Category Company
Founded 2001
Sector Information Technology
DESCRIPTION

Envision Pharma is a global technology and scientific communication company serving the pharmaceutical, biotechnology, and medical device companies. Envision Pharma was founded in 2001 and is based in Horsham, United Kingdom.


DEAL STATS #
Overall 5 of 5
Sector: Internet Software and Services M&A 1 of 1
Type: Add-on Acquisition M&A Deals 5 of 5
State: Massachusetts M&A 1 of 1
Country: United States M&A 3 of 3
Year: 2021 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-11-12 Two Labs

Powell, Ohio, United States

Two Labs LLC is a pharmaceutical services company that provides a portfolio of product commercialization and lifecycle services to pharmaceutical manufacturers. Since its inception in 2003, Two Labs has worked with over 380 manufacturers. This includes supporting over 150 emerging manufacturers with their first product and over 230 pharmaceutical manufacturers with in-market products from pre-launch to loss of exclusivity.

Buy -